Aytu BioPharma (AYTU)
(Delayed Data from NSDQ)
$2.84 USD
+0.04 (1.43%)
Updated Apr 25, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Aytu BioPharma Inc falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 107 | 97 | 66 | 28 | 7 |
Cost Of Goods | 41 | 44 | 36 | 8 | 2 |
Gross Profit | 67 | 52 | 29 | 20 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 84 | 164 | 88 | 41 | 22 |
Income After Depreciation & Amortization | -17 | -112 | -59 | -21 | -17 |
Non-Operating Income | 0 | 1 | 1 | 10 | -10 |
Interest Expense | 0 | 0 | 0 | 3 | 1 |
Pretax Income | -17 | -110 | -58 | -14 | -27 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -17 | -110 | -58 | -14 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -17 | -110 | -58 | -14 | -27 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -2 | -26 | -50 | -15 | -14 |
Depreciation & Amortization (Cash Flow) | 15 | 86 | 9 | 6 | 3 |
Income After Depreciation & Amortization | -17 | -112 | -59 | -21 | -17 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 3.34 | 1.47 | 0.84 | NA | 0.04 |
Diluted EPS Before Non-Recurring Items | -3.52 | -34.40 | -47.20 | NA | -696.00 |
Diluted Net EPS (GAAP) | -5.11 | -75.00 | -69.60 | -60.00 | -696.00 |
Fiscal Year end for Aytu BioPharma Inc falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 22.93 | 22.10 | 30.73 | 22.73 |
Cost Of Goods | NA | 6.73 | 7.32 | 12.17 | 9.99 |
Gross Profit | NA | 16.20 | 14.78 | 18.56 | 12.74 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.84 | 16.29 | 18.62 | 21.31 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.36 | -1.51 | -0.06 | -8.57 |
Non-Operating Income | NA | -1.76 | -6.62 | -0.22 | 1.36 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | 0.61 | -8.12 | -0.28 | -7.20 |
Income Taxes | NA | 0.83 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.22 | -8.12 | -0.28 | -7.20 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.22 | -8.12 | -0.28 | -7.20 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 5.52 | 5.48 | 4.14 | 3.73 |
Diluted EPS Before Non-Recurring Items | NA | -0.04 | -1.48 | 0.16 | -1.93 |
Diluted Net EPS (GAAP) | NA | -0.04 | -1.48 | -0.97 | -1.93 |